| [1] |
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016[J]. CA Cancer J Clin, 2016, 66(1):7-30.
|
| [2] |
Groot VP, Rezaee N, Wu W, et al. Patterns, timing, and predictors of recurrence following pancreatectomy for pancreatic ductal adenocarcinoma[J]. Ann Surg, 2018, 267(5):936-945.
|
| [3] |
Michelakos T, Pergolini I, Castillo CF, et al. Predictors of resectability and survival in patients with borderline and locally advanced pancreatic cancer who underwent neoadjuvant treatment with FOLFIRINOX[J]. Ann Surg, 2019, 269(4):733-740.
|
| [4] |
Jang JK, Byun JH, Kang JH, et al. CT-determined resectability of borderline resectable and unresectable pancreatic adenocarcinoma following FOLFIRINOX therapy[J]. Eur Radiol, 2021, 31(2):813-823.
|
| [5] |
Ferrone CR, Marchegiani G, Hong TS, et al. Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer[J]. Ann Surg, 2015, 261(1):12-17.
|
| [6] |
Marchegiani G, Todaro V, Boninsegna E, et al. Surgery after FOLFIRINOX treatment for locally advanced and borderline resectable pancreatic cancer: increase in tumour attenuation on CT correlates with R0 resection[J]. Eur Radiol, 2018, 28(10):4265-4273.
|
| [7] |
Yoo J, Lee JM, Joo I, et al. Post-neoadjuvant treatment pancreatic cancer resectability and outcome prediction using CT, 18F-FDG PET/MRI and CA 19-9[J]. Cancer Imaging, 2023, 23(1):49.
|
| [8] |
Rayamajhi S, Balachandran A, Katz M, et al. Utility of (18)F-FDG PET/CT and CECT in conjunction with serum CA 19-9 for detecting recurrent pancreatic adenocarcinoma[J]. Abdom Radiol, 2018, 43(2):505-513.
|
| [9] |
蔡伟, 马霄虹, 赵心明. CT评估和预测局部进展期胰腺癌综合治疗疗效的研究进展[J]. 国际医学放射学杂志, 2022, 45(5):572-576.
|
| [10] |
Rose JB, Edwards AM, Rocha FG, et al. Sustained carbohydrate antigen 19-9 response to neoadjuvant chemotherapy in borderline resectable pancreatic cancer predicts progression and survival[J]. Oncologist, 2020, 25(10):859-866.
|
| [11] |
Truty MJ, Kendrick ML, Nagorney DM, et al. Factors predicting response, perioperative outcomes, and survival following total neoadjuvant therapy for borderline/locally advanced pancreatic cancer[J]. Ann Surg, 2021, 273(2):341-349.
|
| [12] |
Boone BA, Steve J, Zenati MS, et al. Serum CA19-9 response to neoadjuvant therapy is associated with outcome in pancreatic adenocarcinoma[J]. Ann Surg Oncol, 2014, 21(13):4351-4358.
|
| [13] |
Beleù A, Calabrese A, Rizzo G, et al. Preoperative imaging evaluation after downstaging of pancreatic ductal adenocarcinoma: a multi-center study[J]. Cancers, 2019, 11(2):267.
|
| [14] |
Panda A, Garg I, Truty MJ, et al. Borderline resectable and locally advanced pancreatic cancer: FDG PET/MRI and CT tumor metrics for assessment of pathologic response to neoadjuvant therapy and prediction of survival[J]. AJR Am J Roentgenol, 2021, 217(3):730-740.
|
| [15] |
Abdelrahman AM, Goenka AH, Alva-Ruiz R, et al. FDG-PET predicts neoadjuvant therapy response and survival in borderline resectable/locally advanced pancreatic adenocarcinoma[J]. J Natl Compr Canc Netw, 2022, 20(9):1023-1032, e3.
|
| [16] |
Oba A, Del Chiaro M, Satoi S, et al. New criteria of resectability for pancreatic cancer: a position paper by the Japanese society of hepato-biliary-pancreatic surgery (JSHBPS)[J]. J Hepatobiliary Pancreat Sci, 2022, 29(7):725-731.
|
| [17] |
Golan T, Barenboim A, Lahat G, et al. Increased rate of complete pathologic response after neoadjuvant FOLFIRINOX for BRCA mutation carriers with borderline resectable pancreatic cancer[J]. Ann Surg Oncol, 2020, 27(10):3963-3970.
|
| [18] |
Golan T, Hammel P, Reni M, et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer[J]. N Engl J Med, 2019, 381(4):317-327.
|
| [19] |
Strickler JH, Satake H, George TJ, et al. Sotorasib in KRAS p.G12C-mutated advanced pancreatic cancer[J]. N Engl J Med, 2023, 388(1):33-43.
|
| [20] |
Moffitt RA, Marayati R, Flate EL, et al. Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma[J]. Nat Genet, 2015, 47(10):1168-1178.
|
| [21] |
Chan-Seng-Yue M, Kim JC, Wilson GW, et al. Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution[J]. Nat Genet, 2020, 52(2):231-240.
|
| [22] |
Edland KH, Tjensvoll K, Oltedal S, et al. Monitoring of circulating tumour DNA in advanced pancreatic ductal adenocarcinoma predicts clinical outcome and reveals disease progression earlier than radiological imaging[J]. Mol Oncol, 2023, 17(9):1857-1870.
|
| [23] |
郑诗凡, 李凡露, 邹思奕, 等. 精准医学时代可切除胰腺癌新辅助治疗的研究现状与展望[J]. 中华普通外科杂志, 2024, 39(1):61-65.
|
| [24] |
Seppälä TT, Zimmerman JW, Suri R, et al. Precision medicine in pancreatic cancer: patient-derived organoid pharmacotyping is a predictive biomarker of clinical treatment response[J]. Clin Cancer Res, 2022, 28(15):3296-3307.
|
| [25] |
Liu Y, Li N, Zhu Y. Pancreatic organoids: a frontier method for investigating pancreatic-related diseases[J]. Int J Mol Sci, 2023, 24(4):4027.
|
| [26] |
国家卫生健康委办公厅. 胰腺癌诊疗指南(2022年版)[J]. 临床肝胆病杂志, 2022, 38(5):1006-1015.
|